Tempus Announces Next Phase of Biological Modeling Efforts

Tempus Announces Next Phase of Biological Modeling Efforts

NEWS

December 19 – Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today an expansion of its biological modeling work to include profiling therapeutic responses across hundreds of unique patient derived organoid models.

Tempus has been working with researchers to better understand how representative in vivo and in vitro modeling systems are of a patient’s actual biology in order to accurately guide unique populations of patients to specific therapies. Building on this work, Tempus has scaled its efforts and introduced high-throughput automation into its organoid lab to carry out therapeutic response profiling. To uncover novel cancer subtypes, these response profiles are then analyzed by deep learning algorithms that also integrate molecular and clinical outcomes information from each patient. This work is in line with a growing body of evidence that biological models have the potential to mirror/capture tumor biology.

 

As with the molecular and clinical data that Tempus collects and structures, Tempus is assembling a library of unique patient derived biological models that can provide the scale necessary to uncover new disease biology.

 

“Tempus has built an infrastructure that allows us to grow thousands  of organoids annually to better understand patient response to disease and therapy,” said Kevin White, President of Tempus. “The hope is that in the not too distant future, we can use the valuable information we gain from organoids to help assign the best treatment for patients at the point of care.”

 

Tempus is currently working with leading academic medical centers and NCI designated cancer centers, hospital networks, community physicians and healthcare stakeholders across the United States on efforts to deliver personalized medicine.

 

About Tempus:

Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians and researchers to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing the health care industry with tools that learn as we gather more data. For more information, visit tempus.com.